Global Cell-Free Protein Expression Market - Restraint
High cost of protein expression systems and lack of effective systems for post-translational modifications are the factors that are expected to hinder growth of the global cell-free protein expression market over the forecast period.
Cell-free protein expression systems are not feasible for large-scale protein expression, as it can turn into a capital-intensive process due to expensive reagents such as phosphate chemicals in nucleotide form and secondary energy sources.
Moreover, the addition of energy and substrate sources in the process can have a negative impact on the cell-free protein expression systems due to short reaction scales which lead to the limited ability of resultant protein foldings during protein expression.
Global Cell-Free Protein Expression Market – Impact of Coronavirus (Covid-19) Pandemic
SARS-CoV-2 (Severe acute respiratory syndrome coronavirus) was first reported from Wuhan, China in December 2019, and was declared as a global pandemic by the World Health Organization (WHO), which designates this SARS-CoV-2 infection as novel Coronavirus (COVID-19). According to the Coronavirus (COVID-19), Weekly Epidemiological Update by the World Health Organization, COVID-19 has spread across the globe infecting over 523 million population leading to more than 6.3 million deaths as of June 5, 2022. The negative impact of COVID-19 on the healthcare domain is huge and it has significantly disrupted the healthcare industries’ entire supply chain, from raw materials to manufacturing and delivery. However, the COVID-19 pandemic had a positive impact on the overall growth of the cell-free protein expression market, owing to use of cell-free protein expression systems to develop new tools, vaccines, and treatments for COVID-19 patients.
For instance, in November 2021, researchers from the North-western University, U.S., developed a cell-free, high-throughput, automated screening platform to rapidly identify anti-severe acute respiratory syndrome coronavirus (SARS-CoV-2) antibodies generated in response to COVID-19 vaccines. These antibodies have high efficacy in preventing SARS-CoV-2 infection and symptomatic disease. In addition to therapeutic usage, these antibodies are widely used in immunoassays for the rapid detection of viral antigens.
Rising cases of chronic diseases such as cancer, diabetes, cardiovascular disease, and others creates a demand for personalized medicine which can be achieved using cell-free protein expression. This is expected to drive growth of the global cell-free protein expression market over the forecast period.
For instance, according to data published in the International Diabetes Federation (IDF) Diabetes Atlas Tenth edition 2021, in December 2021, it is estimated that around 537 million adults (20-79 years) were suffering from diabetes across the globe in 2021. The same source also estimates that the total number of people suffering from diabetes will rise to around 643 million by 2030 and 783 million by 2045, globally.
Global Cell-Free Protein Expression Market - Restraint
High cost of protein expression systems and lack of effective systems for post-translational modifications are the factors that are expected to hinder growth of the global cell-free protein expression market over the forecast period.
Cell-free protein expression systems are not feasible for large-scale protein expression, as it can turn into a capital-intensive process due to expensive reagents such as phosphate chemicals in nucleotide form and secondary energy sources.
Moreover, the addition of energy and substrate sources in the process can have a negative impact on the cell-free protein expression systems due to short reaction scales which lead to the limited ability of resultant protein foldings during protein expression.
Cell-Free Protein Expression Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients